


Hemodiafiltration: practical points


Rukshana Shroff

Great Ormond Street Hospital for Children
London, UK


Effectiveness of RRT modalities



No benefit from increased urea clearance



No. AT RISK										
Standard dose	854	759	630	524	451	382	315	253	197	149
High dose	857	753	637	538	470	399	327	266	219	166



No. AT RISK										
Low flux	851	750	632	525	446	383	307	250	203	149
High flux	860	761	635	537	473	399	335	269	212	160


HEMO study, NEJM, 2002




Outline

- Mechanisms of hemodiafiltration (HDF)
- Theoretical advantages of HDF vs HD
- Clinical benefits of HDF vs conventional HD
 - lessons from adult studies
 - focus on growth and nutrition
- Practical aspects of setting up HDF in your unit



Diffusion



Convection



HDF – clearance by diffusion and convection



HD Low Flux

HD High Flux

HDF

HF

Diffusion

Convection

Adsorption

Low molecules removal


Middle molecules removal



Advantages of HDF

1. Clearance of uraemic solutes across a wide molecular weight range
2. Biocompatibility
3. Hemodynamic stability

1. Clearance on HDF vs HD






β_2 microglobulin clearance

- HDF achieves 70 – 78% reduction in β_2 microglobulin (vs 40 – 50% with high-flux HD)
Thomas et al, Semin Dialy, 2009
- No signs of amyloidosis after 8 yrs on HDF (vs 100% pts on HD have amyloid by 13 yrs)
Canaud et al, NDT, 1998
- 82% reduced incidence of carpal tunnel syndrome and 67% reduced incidence of erosive arthritis
Dember et al, Semin Dialy, 2006

Predialysis β_2 m levels correlate with mortality (HEMO Study)



For every 10 mg /l increase in predialysis B_2M there is a 11% increase in the relative risk of death



Other middle molecules cleared by HDF

- Parathyroid hormone
 - Inflammatory cytokines (IL-6, IL-8, IL-12)
 - Homocysteine
 - Guanidine
 - Polyamines
- Influence endothelial function:**

 - Reduce nitric oxide production
 - Promote AGE formation
 - Affect cell cycle and cause senescence
- Appetite suppressants (leptin, cholecystokinin, tryptophan)
 - Complement factor D



2. Reduced inflammation and oxidative stress

1. reduces inflammation (\downarrow $\text{TNF}\alpha$, IL-6, IL-8, IL-12)
2. suppresses oxidative stress (\downarrow reactive oxygen species and superoxide)
3. improves antioxidant capacity
4. reduces generation of AGEs

Mechanisms

1. Biocompatible membranes
2. 'Ultrapure' dialysate
3. Removal of cytokines



Chronic low-grade exposure to endotoxins

- Chronic inflammation
- Anorexia, poor nutrition and growth, catabolism, loss of lean body mass – cachexia
- Anaemia – poor ESA response
- Risk of atherosclerosis

Malnutrition – inflammation – atherosclerosis complex




3. Hemodynamic stability

1. Fewer intra-dialytic hypotensive episodes
2. Higher UF better tolerated by patient
3. Reduced post-dialysis fatigue
4. Overall better BP control

Mechanisms:

1. Cooling of dialysate
2. Removal of vasodilating mediators
3. High Na content of infusion fluid



Cooling is a part of on-line HDF




Based on Maggiore Q, et al. *Trans Am Soc Artif Intern Organs* 28: 523-527, 1982

Reduced risk of intra-dialytic hypotension on HDF


- Blood returning to the patient is cooler during o-HDF than HD - enhanced energy loss within the extracorporeal system
- In the patients' circulation the mean blood temperature is lower during o-HDF than HD






Cardiovascular and survival advantage of HDF vs HD

1. Dutch HDF Study: CONTRAST




Patients at risk

HD	356	337	307	269
HDF	358	346	324	287





Patients at risk


84	65	53	43	25
76	59	45	36	15




2. Turkish HDF Study: High vs Low Efficiency HDF



3. Spanish HDF Study: High vs Low Efficiency HDF



switching 8 patients from HD to HDF
prevents one death / year







Caution!

**On-line HDF provides better overall
and CV survival only when high
convective volumes are achieved.**

Meta-analysis: all cause mortality



Meta-analysis: cardiovascular deaths




Cochrane review - 2015

- Convective dialysis had no significant effect on all-cause mortality (11 studies, 3396 participants: RR 0.87, 95% CI 0.72 to 1.05).
- Convective dialysis significantly reduced cardiovascular mortality (6 studies, 2889 participants: RR 0.75, 95% CI 0.61 to 0.92).
- Effects on nonfatal cardiovascular events & hospitalisation inconclusive.

Criticism

- Studies on HF were also included under 'convective therapies'
- Studies with different end-points were combined
- Some studies were underpowered to examine CV or all-cause mortality.

Growth on daily HDF



Height SDS

- start: -1.5 ± 0.3
- end: $+0.2 \pm 1.1$
- target height relative to mid-parental height: $+0.3$

Height velocity

- before daily HDF: 3.8 ± 1.1 cm/y
- first year of daily HDF: 14.3 ± 3.8 cm/y
- mean : 10.4 cm/y



Growth study in children

- 15 children on daily HDF; mean age: 7.3 (2.8 – 16.7 yrs)
- 7 converted from PD & 5 from 3/week HD
- Vascular access: fistula (n=13) & catheter (n=4)
- Pre-dilution HDF; Qb & Qd adjusted to achieve a $Kt/V_{urea} \geq 1.4$ per session x 18 hours per week



Dialysis efficiency & tolerance

- Mean weekly $Kt/V_{\text{urea}} = 10$
 - dialysis dose ~ 35% GFR
- Phosphate: 1.39 (1.65 - 0.63) mmol/l
 - despite high protein intake (>2 g/kg/day)
 - 2/15 child on chelators
- CRP – normal in 13/15 (2 children had chronic infections)
- $\beta 2$ microglobulin 13.5 ± 3.5 mg/L

Dialysis dose and growth





Figure 6. Estimated SAN-stdKt/V versus age in two studies in which increased growth rates were linked to intensified dialysis regimens, one with hemodialysis treatments given 3 times/wk by Tom *et al.* (10) and one using 6-times/wk hemodiafiltration by Fischbach *et al.* (11).



Anabolic effect of daily HDF

- Stimulates appetite - removal of circulating satiety factors (leptin, cholecystokinin, tryptophan)
- Correction of metabolic acidosis. Acidosis can:
 - activate the ubiquitin-proteasome pathway & increase protein degradation
 - suppresses endogenous GH secretion
- Minimises inflammatory cytokine release
- ? Removal of somatomedin and gonadotropin inhibitors by HDF
- ? reverses rhGH resistance

Paediatric HDF in Europe



**144 cases of HDF in children in 2013
(~12% of all HD cases)**

The effects of HDF vs conventional HD on growth and cardiovascular markers in children

3H (HDF, Hearts and Height) study

International Pediatric Hemodialysis Network





Hypothesis

Children on HDF compared with HD have improved:

- Cardiovascular risk profile
- Growth and nutritional status
- Quality of life




Primary outcome measures:

- Change in carotid artery intima-media thickness (cIMT) standard deviation score (SDS)
- Change in height SDS

Secondary outcome measures:

- *For nutritional status*
 - Body mass index SDS
 - Markers of appetite regulation and nutritional status
- *For cardiovascular status*
 - 24-hour mean arterial BP SDS
 - Left ventricular mass index
 - Pulse wave velocity SDS
 - Biomarkers of cardiovascular disease
- *Quality of life (QoL) questionnaires*

Recruitment



**185 children
screened**
(from 28 centres
in 10 countries)



20 excluded

- No baseline scans (n = 6)
- Transplanted on day of study (n = 2)
- Did not fulfil inclusion criteria (n = 1)
- No data entry (n = 11)



165 included





Conclusion

- HDF is a superior dialysis modality in adults
PROVIDED high convective clearance is achieved
- Mechanisms:
 - Improved clearance across a wide mol wt range
 - Reduced inflammation
 - Hemodynamic stability
- A study in children is under way



Practical aspects of HDF





Potential limitations for setting up HDF in your centres


1. HDF machine X newer machines can all do HDF
2. Water quality
 - one time installation cost, then 1-3 monthly monitoring
 - must use ultrapure water with all high flux membranes
3. Staff training X provided by company
4. Costs £38/patient/month >HD
5. Lack of paediatric data ✓ We need a study!




Requirements for HDF

1. High-flux membrane
2. Large quantities of IV quality fluid ('ultrapure' dialysate) as replacement fluid
3. Machines with accurate UF control systems

1. Dialysis Membranes





Solute clearance depends on its mol wt



Mol wt
daltons

High-flux membranes




Characteristics of high-flux membranes

1. Flux - Measure of ultrafiltration capacity

Low flux: $K_{uf} < 10 \text{ mL/hr/mm Hg}$

High flux: $K_{uf} > 20 \text{ mL/hr/mm Hg}$



2. Permeability - Measure of the clearance of $\beta 2$ -microglobulin (= middle mol wt solutes)

Low permeability: $\beta 2$ -microglobulin clearance $< 10 \text{ mL/min}$

High permeability: $\beta 2$ -microglobulin clearance $> 20 \text{ mL/min}$

3. Efficiency - Measure of urea (= low mol wt solute) clearance

Low efficiency: $K_{oA} < 500 \text{ mL/min}$

High efficiency: $K_{oA} > 600 \text{ mL/min}$

Performances in vitro

Measured according to
EN 1283

Clearances in vitro (ml/min) +/- 10%

Hemodialysis

UF=0 ml/min, Q_D=500 ml/min

Q_B (ml/min)

Urea

Creatinine

Phosphate

Vitamin B₁₂

Inulin

Hemodiafiltration

UF=60 ml/min, Q_D=500 ml/min

Q_B (ml/min)

Urea

Creatinine

Phosphate

Vitamin B₁₂

Inulin

Polyflux 140H					Polyflux 170H					Polyflux 210H				
200	300	400	500		200	300	400	500		200	300	400	500	
193	262	309	-		196	270	321	-		-	281	339	378	
181	232	266	-		186	243	281	-		-	259	303	334	
174	220	250	-		180	232	266	-		-	249	289	317	
128	149	163	-		137	162	178	-		-	183	203	218	
91	102	109	-		100	113	121	-		-	131	143	151	

KoA for Urea

993

1145

1450

UF-coefficient*

60

70

85

UF-coefficient*

60

70

85

(ml/h mmHg) +/- 20%

Residual blood volume (ml)

Maximum TMP (mmHg)

Recommended Q_B (ml/min)

Sieving coefficients**

Vitamin B₁₂

Inulin

β₂-Microglobulin

Albumin

< 1

600

200-400

1.0

1.0

0.70

<0.01

< 1

600

250-500

1.0

1.0

0.70

<0.01

< 1

600

300-500

1.0

1.0

0.70

<0.01

Specifications

Membrane

Effective surface area (m²)

1.4

1.7

2.1

Fiber dimensions

Wall thickness (μm)

50

50

50

Inner diameter (μm)


215

215

215

2. Substitution fluid to drive UF


Pharmaceutical preparation



1. Large volumes of bagged fluid
2. Cannot use bicarbonate


or

on-line preparation



1. Requires a high dialysate flow rate
2. Ensure fluid is of 'IV' quality

'Ultrapure' water for HDF



Microbiological quality:

- CFU/ml
- EU/ml

100 - 200

0.25 – 2.0

basis for
all fluid
preparation

<100

<0.25

dialysis fluid
in low-flux HD
with synthetic
membranes

<0.1

<0.03

dialysis fluid
in all forms
of HD & HDF

Ultrafilters:

- size selective barrier – filter particles >30-40KD
- Hydrophobic adsorption of bacteria




Type and frequency of H₂O testing

Contaminant	Frequency of testing
Total chlorine	At least weekly
Total viable counts	At least monthly
Endotoxin	At least monthly
Chemical contaminants other than chlorine	At least every 3 months


- Daily and seasonal variations in chlorine and chloramine levels
- Water supplier must know that H₂O is used for dialysis and inform of changes in additives
- If the chlorine level in the source H₂O is consistently low (<0.5mg/L) and chloramines are not used then weekly monitoring of dialysis H₂O is sufficient

Replacement of substitution fluid - pre-dilution vs post-dilution HDF



Post-dilution HDF is superior


1. Requires $\frac{1}{2}$ vol of replacement fluid compared to pre-dilution
2. More efficient removal of low mol wt solutes
3. Risk of high hematocrit and filter clotting
4. Pre-dilution is only useful if low blood flows or hemodynamically unstable patient



3. High UF rate for convective transport


1. membrane properties

- flux
- surface area



2. UF rate - depends on bl flow rate


- optimise access
- AVF preferred to CVL



**Aim for a target convection volume of
12-15L/m² body surface area**


If Q_{UF} too high

Start of dialysis




End of dialysis

if blood volume
reduction is 10%



Increasing hemoconcentration → rise in TMP

Backfiltration in high-flux HD



- Small and unquantified amounts

High flux HD is the poor man's HDF!

With any high flux dialyser the water must be 'ultrapure'



Writing an HDF prescription

- Gambro programme:
 - Pressure control – ‘ULTRA^{CONTROL}’
 - Volume control – calculated at 25 - 30% of Qb

- Fresenius programme:
 - Auto-sub – set TMP

Auto-sub plus – automatically calculates substitution vol based on max allowed TMP



Typical HDF prescription

15 year old boy

$W_t = 42.0\text{kg}$ $SA = 1.4\text{m}^2$

Dialyser Polyflux 140

$Q_b = 300\text{ml/min}$

$Q_d = 500\text{ ml/min}$

Desired wt loss = 1.6L

Calculation if in volume control = %blood flow x number of hours x 60minutes (or consult chart)

$25\% \times 300 \times 4 \times 60 = 18\text{ litres}$

Subtract UF loss (1.6L) = **16.4L** substitution volume